Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity

European Journal of Cancer

Volumn 39, Issue 16, 2003, Pages 2387-2394

  Fujiwara, H ^a   Terashima, M ^b   Irinoda, T ^a   Takagane, A ^a   Abe, K ^a   Nakaya, T ^a   Yonezawa, H ^a   Oyama, K ^a   Takahashi, M ^a   Saito, K ^a   Takechi, T ^c   Fukushima, M ^c   Shirasaka, T ^c  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 Fluorouracil; Antitumour activity; Dihydropyrimidine dehydrogenase; Gastric cancer; S 1; Thymidylate synthase; UFT

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; RNA; TEGAFUR; THYMIDYLATE SYNTHASE; UFT; URACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR XENOGRAFT;

EID: 0141706566     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00513-6     Document Type: Article

References (30)

1. Kelsen D., Atiq O.T., Saltz L.et al. FAMTX versus etoposide, doxorubicin, and cisplatin. a random assignment trial in gastric cancer J. Clin. Oncol. 10:1992;541-548.
2. Schipper D.L., Wagener D.J. Chemotherapy of gastric cancer. Anti-Cancer Drugs. 7:1996;137-149.
3. Carrico C.K., Glazer R.I. Effect of 5-fluorouracil on the synthesis and translation of polyadenylic acid-containing RNA from regenerating rat liver. Cancer Res. 39:1979;3694-3701.
4. Parker W.B., Cheng Y.C. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol. Ther. 48:1990;381-395.
5. Heggie G.D., Sommadossi J.P., Cross D.S., Huster W.J., Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 47:1987;2203-2206.
6. Diasio R.B. Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Huntingt.). 13:1999;17-21.
7. Fujii S., Ikenaka K., Fukushima M., Shirasaka T. Effect of uracil and its derivatives on antitumour activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann. 69:1978;763-772.
8. Baker S.D., Khor S.P., Adjei A.A.et al. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J. Clin. Oncol. 14:1996;3085-3096.
9. Shirasaka T., Shimamato Y., Ohshimo H.et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumour selective cytotoxicity of 5- fluorouracil by two biochemical modulators. Anticancer Drugs. 7:1996;548-557.
10. Meropol N.J., Niedzwiecki D., Hollis D.et al. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 91:2001;1256-1263.
11. Taguchi T. Clinical application of biochemical modulation in cancer chemotherapy. biochemical modulation for 5-FU Oncology. 54:1997;12-18.
12. Pazdur R. Phase II study of UFT plus leucovorin in colorectal cancer. Oncology. 54:1997;19-23.
13. Sulkes A., Benner S.E., Canetta R.M. Uracil-ftorafur. an oral fluoropyrimidine active in colorectal cancer J. Clin. Oncol. 16:1998;3461-3475.
14. Shirasaka T., Nakano K., Takechi T.et al. Antitumour activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 56:1996;2602-2606.
15. Tatsumi K., Fukushima M., Shirasaka T., Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn. J. Cancer Res. 78:1987;748-755.
16. Takechi T., Nakano K., Uchida J.et al. Antitumour activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumour models in rats. Cancer Chemother. Pharmacol. 39:1997;205-211.
17. Sakata Y., Ohtsu A., Horikoshi N., Sugimachi K., Mitachi Y., Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur. J. Cancer. 34:1998;1715-1720.
18. Fukushima M., Satake H., Uchida J.et al. Preclinical antitumour efficacy of S-1. a new oral formulation of 5-fluorouracil on human tumour xenografts Int. J. Oncol. 13:1998;693-698.
19. Hirata K., Horikoshi N., Aiba K.et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumour drug. Clin. Cancer Res. 5:1999;2000-2005.
20. Terashima M., Fujiwara H., Takagane A.et al. Prediction of sensitivity for fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Gastric Cancer. 6:2003;71-81.
21. Etienne M.C., Cheradame S., Fischel J.L.et al. Response to fluorouracil therapy in cancer patients. the role of tumoural dihydropyrimidine dehydrogenase activity J. Clin. Oncol. 13:1995;1663-1670.
22. Lenz H.J., Leichman C.G., Danenberg K.D.et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach. a predictor for primary tumour response and overall survival J. Clin. Oncol. 14:1996;176-182.
23. Terashima M., Irinoda T., Fujiwara H.et al. Role of thymidylate synthase and dihydropyrimidine dehydrogenase on tumour progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res. 22:2002;761-768.
24. Spears C.P., Shahinian A.H., Moran R.G., Heidelberger C., Corbett T.H. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res. 42:1982;450-456.
25. Takechi K., Tamura H., Yamaoka K., Sakurai H. Pharmacokinetic analysis of free radicals by in vivo BCM (blood circulation monitoring)-ESR method. Free Radic. Res. 26:1997;483-496.
26. Uchida J., Umeno Y., Takeda S. [Significance of measuring 5-fluorouracil incorporated into RNA of tumour tissue as a parameter for the antitumour activity of 5-fluorouracil and its analogues]. Gan To Kagaku Ryoho. 19:1992;677-683.
27. Schneider W.C. Phosphorus compounds in animal tissues. III. A comparison of methods for the sedimentation of nucleic acids. J. Biol. Chem. 221:1946;164-167.
28. Jackman A.L., Taylor G.A., Calvert A.H., Harrap K.R. Modulation of antimetabolite effects. effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717 Biochem. Pharmacol. 33:1984;3269-3275.
29. Ohtsu A., Boku F., Nagashima F.et al. A phase I/II study of S-1 plus cisplatin (CDDP) in patients with advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. 2001;165a.
30. Fukushima M., Fujioka A., Uchida J., Nakagawa F., Takechi T. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur. J. Cancer. 37:2001;1681-1687.